At the Medical University of South Carolina, researchers have made an important discovery that could change the way patients ...

According to Cumberland Pharmaceuticals, the newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions by combining ...

Heart attacks have remained the leading cause of death in the United States for over a century. Most treatments focus on ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a ...

On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its ...

In a double-blind randomized controlled, acute cannabidiol administration reduced alcohol craving and cue-induced nucleus ...

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following ...

The Sunday Mail Dr Madzima ZIMBABWE will today be commemorating World AIDS Day, with the main celebrations scheduled for John ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

A research team has developed a Mass Spectrometry technology-based technique to rapidly assess paracetamol levels from saliva.

The major findings of this study of exacerbations of COPD can be summarised as follows: (a) among patients with elevated CRP, those receiving NAC were more likely to have this marker normalised ...